logo
logo
AI

Discover the World’s Fastest Business Insights

Get real-time alerts on funding rounds, executive hires, acquisitions, and more— plus verified contact details and AI-powered outreach to connect faster.
Sign up now to unlock exclusive data and opportunities.

Dice Molecules Announces $60 Million Series C-1 Financing

Dice Molecules Announces $60 Million Series C-1 Financing

08/24/21, 12:35 PM
Location
https://purecatamphetamine.github.io/country-flag-icons/3x2/US.svgsan francisco
Money raised
$60 million
Round Type
series c
DiCE Molecules, a biopharmaceutical company leveraging its proprietary DNA-encoded library platform to discover and develop next-generation therapeutics in immunology and other therapeutic areas, today announced the completion of its $60 million Series C-1 financing. The financing was led by RA Capital Management and Sands Capital, with participation from new investors Janus Henderson Investors, Deep Track Capital and Logos Capital. Existing investors Northpond Ventures, Eventide Asset Management, Driehaus Capital Management, Soleus Capital, New Leaf Venture Partners, Osage University Partners and Asymmetry Capital Management also participated in the round. With the closing of this Series C-1 financing round, the Company has raised approximately $200 million to date.

Company Info

Company
Di Ce Molecules
Location
san francisco, california, united states
Additional Info
DiCE Molecules is a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. DiCE Molecules is initially focused on developing oral therapeutics against well validated targets in immunology, with the goal of achieving comparable potency to their systemic biologic counterparts, which have demonstrated the greatest therapeutic benefit to date in these disease areas. The Company’s DELSCAPE platform is designed to discover selective oral small molecules with the potential to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. DiCE Molecules’ lead therapeutic candidate, S011806, is an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17 (IL-17), which is a validated drug target implicated in a variety of immunology indications. DiCE Molecules is also developing oral therapeutic candidates targeting α4ß7 integrin and αVß1/αVß6 integrin for the treatment of inflammatory bowel disease and idiopathic pulmonary fibrosis, respectively. For additional information, please visit www.dicemolecules.com.
G2 High Performer Badge

Never Miss an Opportunity: Your #1 Sales Intelligence Tool

Get lightning-fast updates on funding rounds, executive hires, contract awards, and more—powered by AI-driven insights to help you connect with the right prospects first.